Publications in collaboration with researchers from Hospital Clinic Barcelona (23)

2024

  1. Safety of biologic therapy in combination with methotrexate in moderate to severe psoriasis: a cohort study from the BIOBADADERM registry

    British Journal of Dermatology, Vol. 190, Núm. 3, pp. 355-363

2022

  1. Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience

    Actas Dermo-Sifiliograficas, Vol. 113, Núm. 4, pp. 401-406

  2. Monkeypox outbreak in Spain: clinical and epidemiological findings in a prospective cross-sectional study of 185 cases*

    British Journal of Dermatology, Vol. 187, Núm. 5, pp. 765-772

  3. The risk of hepatic adverse events of systemic medications for psoriasis: a prospective cohort study using the BIOBADADERM registry

    Journal of Dermatological Treatment, Vol. 33, Núm. 4, pp. 2110-2117

  4. Women with moderate-to-severe psoriasis in Spain (BIOBADADERM registry) breastfeed less when compared with general population

    Journal of the European Academy of Dermatology and Venereology

2021

  1. Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis

    Journal of the American Academy of Dermatology, Vol. 84, Núm. 2, pp. 513-517

2020

  1. Long-term safety of nine systemic medications for psoriasis: A cohort study using the Spanish Registry of Adverse Events for Biological Therapy in Dermatological Diseases (BIOBADADERM) Registry

    Journal of the American Academy of Dermatology, Vol. 83, Núm. 1, pp. 139-150

  2. The risk of urinary tract infections in patients with psoriasis on systemic medications in Biobadaderm Registry: A prospective cohort study

    Journal of the American Academy of Dermatology, Vol. 82, Núm. 3, pp. 738-741

2018

  1. Change over time in the rates of adverse events in patients receiving systemic therapy for psoriasis: A cohort study

    Journal of the American Academy of Dermatology, Vol. 78, Núm. 4, pp. 798-800

2017

  1. Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm

    Journal of the European Academy of Dermatology and Venereology, Vol. 31, Núm. 10, pp. 1700-1708

  2. Infections in Moderate to Severe Psoriasis Patients Treated with Biological Drugs Compared to Classic Systemic Drugs: Findings from the BIOBADADERM Registry

    Journal of Investigative Dermatology, Vol. 137, Núm. 2, pp. 313-321

  3. Should tumour necrosis factor antagonist safety information be applied from patients with rheumatoid arthritis to psoriasis? Rates of serious adverse events in the prospective rheumatoid arthritis BIOBADASER and psoriasis BIOBADADERM cohorts

    British Journal of Dermatology, Vol. 176, Núm. 3, pp. 643-649

2016

  1. Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis

    Journal of the European Academy of Dermatology and Venereology, Vol. 30, Núm. 11, pp. 1942-1950

2015

  1. Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time

    Actas Dermo-Sifiliograficas, Vol. 106, Núm. 8, pp. 638-643

  2. Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time

    Actas dermo-sifiliograficas, Vol. 106, Núm. 8, pp. 638-643

  3. Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry

    Journal of the European Academy of Dermatology and Venereology, Vol. 29, Núm. 1, pp. 156-163

  4. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: An observational study from national BIOBADADERM registry

    Journal of the European Academy of Dermatology and Venereology, Vol. 29, Núm. 5, pp. 858-864

  5. Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice

    Journal of Dermatological Treatment, Vol. 26, Núm. 6, pp. 502-506

2014

  1. Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: Results of the Biobadaderm Registry

    Journal of the European Academy of Dermatology and Venereology, Vol. 28, Núm. 7, pp. 907-914

2013

  1. Latent tuberculosis infection and active tuberculosis in patients with psoriasis: A study on the incidence of tuberculosis and the prevalence of latent tuberculosis disease in patients with moderate-severe psoriasis in Spain. BIOBADADERM registry

    Journal of the European Academy of Dermatology and Venereology, Vol. 27, Núm. 11, pp. 1366-1374